Membrane-Targeting Neolignan-Antimicrobial Peptide Mimic Conjugates to Combat Methicillin-Resistant Staphylococcus...

Area of Science:

• Medicinal Chemistry
• Microbiology
• Pharmacology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant public health threat due to its resistance to conventional antibiotics.
• There is an urgent need for novel antimicrobial agents to combat MRSA infections effectively.

Purpose of the Study:

• To synthesize novel neolignan-antimicrobial peptide (AMP) mimic conjugates.
• To evaluate the in vitro and in vivo anti-MRSA activity of these conjugates.
• To investigate the mechanism of action and safety profile of the most potent compounds.

Main Methods:

• Synthesis of neolignan isomagnolone, its isomer, and a series of neolignan-AMP mimic conjugates.
• In vitro and in vivo testing of anti-MRSA activity, including killing kinetics and resistance frequency.
• Assessment of toxicity, effects on bacterial biofilms, and mechanism of action studies (bacterial membrane binding, ROS generation, leakage assays).

Main Results:

• Conjugates III5 and III15 demonstrated potent in vitro and in vivo anti-MRSA activity, comparable to vancomycin.
• These conjugates exhibited fast-killing kinetics, low resistance frequency, and low toxicity.
• Mechanism studies revealed disruption of bacterial cell membranes by binding to phosphatidylglycerol (PG) and cardiolipin (CL), leading to increased reactive oxygen species (ROS) and leakage of cellular contents.

Conclusions:

• Neolignan-AMP mimic conjugates, particularly III5 and III15, represent promising therapeutic candidates for treating MRSA infections.
• Their multifaceted mechanism of action, including membrane disruption and rapid bactericidal effects, suggests a reduced likelihood of resistance development.
• Further development of these conjugates could lead to effective new treatments against challenging MRSA infections.